Blood-brain barrier permeability and gadolinium benefits and potential pitfalls in research

JAMA Neurology

Volumn 73, Issue 1, 2016, Pages 13-14

  Montagne, Axel ^a   Toga, Arthur W ^a   Zlokovic, Berislav V ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GADOBENATE DIMEGLUMINE; GADODIAMIDE; GADOLINIUM PENTETATE MEGLUMINE; GADOTERATE MEGLUMINE; GADOTERIDOL; CONTRAST MEDIUM; GADOLINIUM;

ALZHEIMER DISEASE; BIOACCUMULATION; BLOOD BRAIN BARRIER; BRAIN REGION; CONTRAST ENHANCEMENT; DEMENTIA; DRUG HALF LIFE; DRUG RETENTION; DRUG SAFETY; HUMAN; NEUROIMAGING; NONHUMAN; NOTE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; UNSPECIFIED SIDE EFFECT; ANIMAL; CAPILLARY PERMEABILITY; MEDICAL RESEARCH; METABOLISM; NERVOUS SYSTEM DISEASES; PHYSIOLOGY; TRENDS;

ANIMALS; BIOMEDICAL RESEARCH; BLOOD-BRAIN BARRIER; CAPILLARY PERMEABILITY; CONTRAST MEDIA; GADOLINIUM; HUMANS; NERVOUS SYSTEM DISEASES;

EID: 84954215881     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2015.2960     Document Type: Note

References (9)

1. Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat Rev Neurosci. 2011;12(12): 723-738.
2. Kanal E, TweedleMF. Residual or retained gadolinium: Practical implications for radiologists and our patients. Radiology. 2015;275(3): 630-634.
3. Montagne A, Barnes SR, SweeneyMD, et al. Blood-brain barrier breakdown in the aging human hippocampus. Neuron. 2015;85(2): 296-302.
4. Kanda T, Ishii K, Kawaguchi H, Kitajima K, Takenaka D. High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: Relationship with increasing cumulative dose of a gadolinium-based contrast material. Radiology. 2014;270(3): 834-841.
5. McDonald RJ, McDonald JS, Kallmes DF, et al. Intracranial gadolinium deposition after contrast-enhanced MR imaging. Radiology. 2015; 275(3): 772-782.
6. Kanda T, OsawaM, Oba H, et al. High signal intensity in dentate nucleus on unenhanced T1-weighted MR images: Association with linear vs macrocyclic gadolinium chelate administration. Radiology. 2015;275(3): 803-809.
7. Radbruch A,Weberling LD, Kieslich PJ, et al. Gadolinium retention in the dentate nucleus and globus pallidus is dependent on the class of contrast agent. Radiology. 2015;275(3): 783-791.
8. Robert P, Lehericy S, Grand S, et al. T1-weighted hypersignal in the deep cerebellar nuclei after repeated administrations of gadolinium-based contrast agents in healthy rats: Difference between linear and macrocyclic agents. Invest Radiol. 2015; 50(8): 473-480.
9. US Food and Drug Administration. FDA drug safety communication: FDA evaluating the risk of brain deposits with repeated use of gadolinium-based contrast agents for magnetic resonance imaging (MRI). http: //www.fda.gov /Drugs/DrugSafety/ucm455386.htm. Accessed July 27, 2015.